Abstract: System and computer program product are provided to configure a path between nodes through a fabric in a fibre channel storage area network (SAN). A node name is provided for a target node on the SAN and a port name is provided for each port in the target node. A relationship is established in a data structure between each port name and a slot in which each port is physically located in the target node. Prior to configuring a path between a source node and a port in the target node, the ports which are physically connected and logged in to the fabric are identified by port address. The port names corresponding to the port addresses are then identified. The port names are used to generate interface_ids of the ports corresponding to the physical slots in which the ports are located. A data structure is created to maintain the relationship between interface_ids and port names.

Abstract: The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above the pre-therapy level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the area treated using light), so long as the light therapy conditions favor apoptosis over necrosis. The volume of abnormal tissue destroyed is maximized to the extent possible, reducing tumor load, which reduces an amount of immunosuppressive factors in the body, enabling stimulation of the immune system to be successful.

Abstract: The efficacy of light activated therapy treatment is enhanced by use of additional therapeutic agents. Abnormal tissue is destroyed by light activated therapy, and the associated administration of one or more additional therapeutic agents can synergistically enhance the therapy. For example, the concepts disclosed herein encompass the use of the following agents in combination with light activated drug therapy: (1) agents that selectively inhibit heat shock protein 90 (Hsp90); (2) agents that inhibit the Hedgehog pathway (which is believed to play a central role in allowing the proliferation and survival of certain cancer-causing cells, and which is implicated in many of the most deadly cancers); and, (3) agents for reducing the anti-apoptotic effects of Bcl-2 or Bcl-xL. These agents can be used with light activated drug therapy individually, or in various combinations and permutations.

Abstract: A method and system is used to locate tissue for removal during a resection. The system includes a container that holds a photoactivatable agent capable of binding with unwanted tissue at a treatment site, a light source, and a viewing device. The light source is adapted to continuously output light that causes fluorescence of the photoactivatable agent in unwanted tissue. The system provides fluorescence-enhanced viewing of the treatment site through the viewing device. The viewing device has a filter that filters out light from the light source that is reflected from the treatment site while allowing a fluorescence emission from the photoactivatable agent to pass therethrough to each eye of the user. The light from the light source and the fluorescence emission are in different regions of the energy spectrum.

Abstract: Light generating devices for illuminating portions of vascular tissue to administer photodynamic therapy, and usable with, or including a distal protection device. A first device includes a hollow tip, a flushing lumen, a guidewire lumen, and at least one of a light source, and a hollow light transmissive shaft that is adapted to accommodate a light source. If desired, the device can include a balloon, so that a portion of a body lumen between the balloon and the distal protection device is isolated when the balloon is inflated. A second device includes inner and outer catheters, the outer catheter including a balloon, and the inner catheter including a light source encompassed by another balloon. Yet another device is a catheter having two balloons and a sleeve extending there between. Within the sleeve, the catheter includes a light source and an expanding member.

Abstract: A light delivery system to provide light treatment to a patient includes a catheter assembly having a plurality of light sources that transmit light towards a target site within a patient. In one embodiment, the light delivery system has a plurality of light sources mounted to a flexible transparent base that extends at least partially through a distal tip of the catheter assembly. The light sources can be wire bonded or mounted in a flip chip arrangement onto the base. In one embodiment to produce the distal tip, an array of light energy sources can be held by an array of holders of a fixture device. A vacuum is applied to secure each light energy source in a corresponding holder. While the vacuum is applied, the energy sources are electrically connected by wire bonding. The vacuum can be reduced or stopped thereby permitting removal of the light energy sources from the fixture device.

Abstract: An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask.

Abstract: The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above a normal level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the region treated using light). By further stimulating the immune system using an anti-CTLA-4 antibody, the systemic destruction of abnormal tissue is enhanced.

Abstract: Systems, devices, and methods for releasing one or more cell components from a photosynthetic organism. A bioreactor system is operable for growing photosynthetic organisms. Some of the methods include contacting the photosynthetic organism with an energy-activatable sensitizer, and activating the energy-activatable sensitizer, thereby releasing a cellular component from at least one of, for example, a membrane structure, tubule, vesicle, cisterna, organelle, cell compartment, plastid, or mitochondrion, associated with the photosynthetic organisms.

Abstract: Methods, system and computer program product are provided to improve the efficiency of data transfers in a PPRC environment. Any or all of three features may be implemented, each of which reduces the number of round trips required for the exchange of handshaking, data and control information. A first feature includes disabling the “transfer ready” acknowledgment which normally occurs between a primary storage controller and a secondary storage controller. A second feature includes pre-allocating payload and data buffers in the secondary storage controller. A third feature includes packaging write control information with a write command in an extended command descriptor block (CDB). Such a step eliminated the need for a separate transmission of the write control information. The CDB is transmitted along with a data block from the primary storage controller to the secondary storage controller and placed in the respective, pre-allocated buffers. Data may also be pipelined to the secondary.

Abstract: A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.

Abstract: Methods, system and computer program product are provided to configure a path between nodes through a fabric in a fibre channel storage area network (SAN). A node name is provided for a target node on the SAN and a port name is provided for each port in the target node. A relationship is established in a data structure between each port name and a slot in which each port is physically located in the target node. Prior to configuring a path between a source node and a port in the target node, the ports which are physically connected and logged in to the fabric are identified by port address. The port names corresponding to the port addresses are then identified. The port names are used to generate interface_ids of the ports corresponding to the physical slots in which the ports are located. A data structure is created to maintain the relationship between interface_ids and port names.

Abstract: Systems, devices, and methods for releasing one or more cell components from a photosynthetic organism. A bioreactor system is operable for growing photosynthetic organisms. Some of the methods include contacting the photosynthetic organism with an energy-activatable sensitizer, and activating the energy-activatable sensitizer, thereby releasing a cellular component from at least one of, for example, a membrane structure, tubule, vesicle, cisterna, organelle, cell compartment, plastid, or mitochondrion, associated with the photosynthetic organisms.

Abstract: Light generating devices for illuminating portions of vascular tissue to administer photodynamic therapy, and usable with, or including a distal protection device. A first device includes a hollow tip, a flushing lumen, a guidewire lumen, and at least one of a light source, and a hollow light transmissive shaft that is adapted to accommodate a light source. If desired, the device can include a balloon, so that a portion of a body lumen between the balloon and the distal protection device is isolated when the balloon is inflated. A second device includes inner and outer catheters, the outer catheter including a balloon, and the inner catheter including a light source encompassed by another balloon. Yet another device is a catheter having two balloons and a sleeve extending there between. Within the sleeve, the catheter includes a light source and an expanding member.

Abstract: System and computer program product are provided to configure a path between nodes through a fabric in a fibre channel storage area network (SAN). A node name is provided for a target node on the SAN and a port name is provided for each port in the target node. A relationship is established in a data structure between each port name and a slot in which each port is physically located in the target node. Prior to configuring a path between a source node and a port in the target node, the ports which are physically connected and logged in to the fabric are identified by port address. The port names corresponding to the port addresses are then identified. The port names are used to generate interface_ids of the ports corresponding to the physical slots in which the ports are located. A data structure is created to maintain the relationship between interface_ids and port names.

Abstract: This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.

Abstract: A system and method for excitation of photosensitizers is configured to provide desired illumination on targeted eye tissue. The excitation system includes an optical module that generates illumination and a controller to power the optical module and control the shape, intensity or energy level, and duration of the illumination. The optical module includes a contact portion for interfacing with the eye, a treatment beam portion including a light emitter array to generate shaped light patterns and optics to focus the light patterns onto the eye, and a visualization portion to provide visual feedback of treatment through a visualization interface coupled with a microscope. A typical treatment involves the optical module being placed on a diseased eye of a patient by a clinician to project illumination on a diseased portion of the eye. The clinician typically views the eye through the microscope and the optical module during treatment.

Abstract: A log-in resource release system includes a set of lists for managing log-in requests to a processing cluster input/output port from host server input/output ports. Host servers that have been granted memory structures within a memory storage device (“configured hosts”) are granted priority access to a storage processing device's input/output port (“cluster port”). If the cluster port has exhausted its log-in resources, log-on requests from non-configured hosts will be not be accepted. New log-in requests from configured hosts will cause a host connected at a link or transport layer but not an upper layer to be logged off. If no hosts are connected only at the link or transport layer, a non-configured host connected at an upper layer will be logged off. If only configured hosts are connected and only at the upper layer, the log-on request by the configured host will be denied.

Abstract: A method of error management in a data storage system having a target device, with the target device receiving commands from a first initiator and the target device concurrently receiving commands from a second initiator. The target device is typically a storage device operating as a PPRC secondary. A first initiator is a device which communicates with the target device through small computer systems interface (SCSI) protocol. The first initiator is typically a host computer or server. The second initiator communicates with the target device through peer-to-peer remote copy PPRC initiator mode commands. The second initiator is typically a separate storage device in a peer-to-peer remote copy (PPRC) relationship with the target device. The method consists of managing errors associated with a command sent to the target device from the first initiator independently from the management of errors associated with a command sent to the target device from the second initiator.

Abstract: Computer networks are provided with a resource efficient ability to generate link performance statistics. Two counters accumulates the number of I/O operations processed by a link and the time required by the link to complete each I/O operation. The average link utilization per I/O operation may then be calculated. The number of operations per second for a link may be computed by dividing the output from the first counter by a predetermined period of time and the average number of operations using the link may be computed by dividing the output from the second counter by the predetermined period of time. An optional third counter may be employed to accumulate the number of bytes transferred by a link during each I/O operation and used to compute the average size of an I/O operation. The generated statistics are useful for such activities as problem resolution, load balancing and capacity planning.